Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) have received a consensus recommendation of “Hold” from the fifteen brokerages that are presently covering the stock, MarketBeat.com reports. Nine investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $106.08.

ITCI has been the topic of several analyst reports. Mizuho downgraded Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $140.00 to $132.00 in a research report on Monday, February 24th. Leerink Partnrs cut Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Royal Bank of Canada reissued a “sector perform” rating and issued a $132.00 target price (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Piper Sandler restated a “neutral” rating and set a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Finally, Cantor Fitzgerald upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 14th.

Intra-Cellular Therapies Trading Up 0.0 %

ITCI opened at $131.81 on Friday. The company’s 50 day moving average is $129.12 and its 200 day moving average is $99.63. The company has a market cap of $14.04 billion, a price-to-earnings ratio of -151.50 and a beta of 0.69. Intra-Cellular Therapies has a 12-month low of $64.09 and a 12-month high of $131.87.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The business had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. As a group, analysts predict that Intra-Cellular Therapies will post -0.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Accredited Wealth Management LLC purchased a new stake in shares of Intra-Cellular Therapies in the fourth quarter worth about $28,000. True Wealth Design LLC bought a new position in shares of Intra-Cellular Therapies during the 3rd quarter valued at approximately $32,000. GAMMA Investing LLC grew its holdings in shares of Intra-Cellular Therapies by 46.3% in the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 240 shares in the last quarter. Venturi Wealth Management LLC purchased a new position in shares of Intra-Cellular Therapies in the fourth quarter valued at $96,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in Intra-Cellular Therapies in the third quarter worth $97,000. Institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.